Gain detailed insights into the trading activity of Congress members for West Pharmaceutical Servs on our government trades page. Stay updated on how elected officials are investing in WST.

West Pharmaceutical Servs - Government Trades

West Pharmaceutical Servs

West Pharmaceutical Services is based in Pennsylvania, us, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

corporate_office_thumb

Long Ideas

News

Markets

Media

Trading Ideas

APLD

NVDA

On CNBC&#39;s &#34;Halftime Report Final Trades,&#34; Tim Seymour of Seymour Asset Management picked Cameco Corporation. 

Cameco, Applied Digital, West Pharmaceutical And More On CNBC&#39;s &#39;Final Trades&#39;

syringe-4544448_1920

Earnings

Guidance

Dividends

Health Care

Movers

General

West Pharmaceutical Services reported Q3 adjusted EPS of $1.85, beating estimates, with $746.9 million in sales. Updated 2024 guidance reflects higher EPS and sales.

West Pharmaceutical&#39;s Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend

Intraday Update

ACIC

ASTS

CBRE

Laboratory Corporation Of America Holdings

PEGA

PLXS

POOL

RKLB

TMUS

TSLA

VKTX

ZLAB

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday

AFRM

ALAB

ELYM

EOSE

IREN

IRTC

NTNX

PSNY

STVN

VEEV

Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems And Other Big Stocks Moving Higher On Thursday

Bull Wall Street

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Federal Reserve

Tech

ETFs

BBWI

CSCO

SPDR Dow Jones Industrial Average ETF Trust

DXCM

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TEAM

TTWO

ULTA

S&amp;P 500 and Nasdaq 100 indices gain for seventh straight day, marking best weekly performance since October 2023 on positive economic data. SPY and QQQ close with modest daily gains while DIA has best week since December 2023. 

S&amp;P 500, Nasdaq 100 Mark Seventh Straight Positive Session, Strongest Week Since October 2023: Friday&#39;s Top Movers

Ford  F-150 - Lightning

DELL

LULU

MBLY

MEDP

SMCI

STLA

Top 10 worst performers last week: EW (-28.05%), F (-19.12%), STM (-17.60%), TER (-16.25%), MBLY (-14.61%), STLA (-13.07%), VRT (-12.04%), SMCI (-11.68%), WST (-11.37%), DELL (-11.26%), UPS (-10.96%), LKQ (-10.89%)

Ford, Stellantis And Dell Are Among Top 12 Large Cap Losers Last Week (July 21-July 27): Are The Others In Your Portfolio?

ATPC

BALY

BLMZ

CERO

COOP

CTNT

EZFL

FORM

GSHD

HOTH

INDV

JBHT

KALU

KDLY

POAI

RBBN

SHYF

SLGL

SLNA

SLRX

TIVC

TWOU

XCUR

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Analyst Ratings

HOLX

West Pharmaceutical Services, Inc. (NYSE: WST) is well poised for growth, backed by the robust Proprietary Products segment and sustained strength in research and development (R&amp;D). However, foreign exchange volatility is a concern.

Reasons to Hold West Pharmaceutical in Your Portfolio Now

IDXX

West Pharmaceutical Services, Inc. (NYSE: WST) reported first-quarter 2024 adjusted earnings per share (ETF:EPS) of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The bottom line, however, was down 21.2% year over year.

West Pharmaceutical Q1 Earnings Beat, HVP Sales Weak

Wall Street bull

Analyst Color

Sector ETFs

New ETFs

Retail Sales

PENN

TRIP

TWLO

YETI

ZBRA

US stocks surge on strong earnings and speculation of Fed rate cuts. S&amp;P 500 rebounds past 5000, Nasdaq 100 pauses. Small caps outperform. Tesla, Wells Fargo, and CBRE rally on positive news while Deer &amp; Antero Resources shares drop. Other companies react to earnings.

S&amp;P Reclaims 5,000 As Disappointing Retail Sales Put Fed Cuts Back On Track, Small Caps Shine: What&#39;s Driving Markets Thursday?

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Services Inc

WEST HOLDINGS CORP by West Holdings Corp.

West Holdings Corp

WESTELL TECHS INC A NEW by Westell Technologies, Inc.

Westell Technologies Inc

WESTLIN CORP by Westlin Corp.

WESTERN URANIUM&VANADIUM by Western Uranium & Vanadium Corp.

Western Uranium & Vanadium Corp

WESTPORTS HLDGS BHD ORD by WESTPORTS HLDGS BHD

Westports Holdings Bhd

Wrapped stETH - United States Dollar

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 29.05% since its last report. The company recently reported that it has 1.50 million shares sold short, which is 2.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737045918_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(WST) - Analyzing West Pharmaceutical Servs's Short Interest

Citigroup analyst Thomas Palmer initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Buy rating and announces Price Target of $400.

Price Target

Initiation

Citigroup Initiates Coverage On West Pharmaceutical Servs with Buy Rating, Announces Price Target of $400

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has fallen 10.21% since its last report. The company recently reported that it has 1.16 million shares sold short, which is 2.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734718511_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into West Pharmaceutical Servs's Recent Short Interest

B of A Securities analyst Derik De Bruin maintains West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Buy and raises the price target from $350 to $355.

B of A Securities Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $355

Wolfe Research analyst Doug Schenkel initiates coverage on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with a Peer Perform rating.

Wolfe Research Initiates Coverage On West Pharmaceutical Servs with Peer Perform Rating

WIIM

West Pharmaceutical Services shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $350 to $390.

UBS analyst John Sourbeer upgrades West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) from Neutral to Buy and raises the price target from $350 to $390.

Upgrades

UBS Upgrades West Pharmaceutical Servs to Buy, Raises Price Target to $390

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/11/15/final-trade-west-pharma-cameco-ishares-biotechnology-etf-and-applied-digital-corp.html">Halftime Report Final Trades</a>,&#8221; Tim Seymour of Seymour Asset Management picked Cameco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>).
On Nov. 7, Cameco posted a loss for the third quarter but raised its FY24 revenue guidance.
Julie Biel of Kayne Anderson Rudnick named West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), saying this health care <a href="https://www.benzinga.com/quote/WST/earnings">trade is &#8220;overblown.&#8221;</a>
On Oct. 24, West Pharmaceutical Services reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50. The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $746.9 million, beating the consensus of $709.62 million.
Don't forget to check out ou <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Karen Finerman of Metropolitan Capital Advisors said she likes iShares Biotechnology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBB#NYSE">IBB</a>) here.
Steven Grasso of Grasso Global Inc. named Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) as his final trade.
Nvidia's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 13F fling, last week, showed it purchased 7.72 million Applied Digital shares worth $63.66 million as of Sept. 30, which translates into close to a 3.6% stake in Applied Digital, which had 215.36 million <a href="https://www.benzinga.com/news/24/11/42016662/nvidia-reveals-3-6-stake-in-applied-digital-stock-soars">outstanding shares as of Oct. 8,</a>
Price Action:
<ul>
<li>West Pharmaceutical shares dipped 7% to close at $314.49 on Friday.</li>
<li>Cameco shares gained by 0.9% to settle at $53.59 during Friday's session.</li>
<li>iShares Biotechnology ETF fell by 4.8% during Friday's session.</li>
<li>Applied Digital shares gained 5.4% to settle at $7.23.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Image: Courtesy of Cameco

Cameco, Applied Digital, West Pharmaceutical And More On CNBC's 'Final Trades'

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 6.9% since its last report. The company recently reported that it has 1.54 million shares sold short, which is 2.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731087922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 6.9% since its last report. The company recently reported that it has 1.54 million shares sold short, which is 2.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730925012_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into West Pharmaceutical Servs's Recent Short Interest

On Thursday, West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.50</a>.
The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $746.9 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41511044/west-announces-third-quarter-2024-results-increases-fiscal-year-2024-guidance-and-declares-fourth-" rel="noreferrer noopener">consensus of $709.62 million</a>.
The Proprietary Products Segment&#8217;s sales declined by 0.2% to&nbsp;$601.4 million, and the organic net sales decline was 0.5%.
High-value products (components and devices) represented over 75% of segment net sales in the period, led by customer demand for self-injection device platforms.
Sales in the Contract-Manufactured Products Segment grew marginally by 0.4% to&nbsp;$145.5 million. Organic net sales were consistent with the third quarter of last year.
Segment performance was driven by growth in self-injection devices for obesity and diabetes, offset by a decrease in sales of healthcare diagnostic devices.
Eric M. Green, President, CEO, and Chair of the Board, commented, &#8220;We are pleased to report solid third-quarter results&#8230;This reinforces my confidence in West&#8217;s execution capabilities as we continue to deliver our proven market-led strategy and attractive long-term potential.&#8221;
Dividend: West Pharmaceutical approved the fourth quarter 2024 dividend of $0.21/share, up 5% from the $0.20/share paid in the four preceding quarters. The dividend will be paid on&nbsp;November 20 to shareholders of record as of&nbsp;November 13.
Guidance: West Pharmaceutical Services raised its fiscal year 2024 guidance on favorable currency movements.
The company expects 2024 adjusted EPS guidance of $6.55-$6.75 compared to prior guidance of $6.35-$6.65 and consensus of $6.51.
West Pharmaceutical Services forecasts 2024 sales of $2.875 billion-$2.905 billion compared to prior guidance of $2.87 billion-$2.9 billion and a consensus of $2.874 billion.
Price Action: At the last check on Thursday, WST stock was up 17.60% at $337.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41516084/nvidia-chases-growth-in-india-ai-partnerships-with-reliance-infosys-wipro-expanding-into-robotics-an" target="_blank" rel="noreferrer noopener">Nvidia Chases Growth in India: AI Partnerships With Reliance, Infosys, Wipro, Expanding into Robotics And Key Industries</a>.</li>
</ul>

West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) rose during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41515619/delivery-giant-ups-breaks-revenue-miss-streak-after-10-quarters-stock-soars">better-than-expected quarterly EPS and sales.</a>
UPS reported consolidated revenue growth of 5.6% year-over-year to $22.2 billion, beating the consensus of $22.14 billion. Adjusted EPS was $1.76, up 12.1% YoY, above the consensus of $1.63.
United Parcel Service shares jumped 5% to $137.93 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares jumped 31.6% to $6.82 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) gained 22.8% to $337.89 after the company reported better-than-expected third-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) climbed 20.7% to $345.82 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates. Also, the company increased its fourth-quarter dividend.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 18.7% to $71.65 after the company reported better-than-expected third-quarter EPS results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.7% to $14.67 after the company reported better-than-expected third-quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) surged 16.8% to $12.09 after the company provided updates on hurricane loss amounts and announced it expects a positive net income for the third quarter.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 16.5% to $248.93 following better-than-expected quarterly earnings.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) climbed 15.6% to $66.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.2% to $33.33 after the company presented data from its ongoing Phase 1a/1b study of ZL-1310 for previously treated extensive-stage small cell lung cancer at the EORTC-NCI-AACR Symposium 2024.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 14.2% to $79.66.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 13.2% to $29.72 after the company announced it bagged a contract with the Space Development Agency as the prime contractor to the US Government.</li>
<li>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) gained 11.2% to $7.70 after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS above estimates.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) rose 10% to $109.18 following a third-quarter EPS beat and guidance above consensus estimates.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 9.9% to $149.00 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 9.9% to $12.00 after Keybanc maintained an Overweight rating on the stock and raised its price target from $11 to $12.</li>
<li>CBRE Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NASDAQ">CBRE</a>) gained 9.7% to $135.12 after the company reported better-than-expected third-quarter financial results and raised its FY24 adjusted EPS guidance above estimates.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 8.2% to $629.72 following upbeat quarterly earnings.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 7.6% to $236.52 following strong quarterly earnings.</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) gained 7.5% to $377.11 following strong quarterly sales.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) gained 4.1% to $230.00 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

High-rolling investors have positioned themselves bullish on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in WST often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 18 options trades for West Pharmaceutical Servs. This is not a typical pattern.
The sentiment among these major traders is split, with 83% bullish and 16% bearish. Among all the options we identified, there was one put, amounting to $25,880, and 17 calls, totaling $3,378,366.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $390.0 for West Pharmaceutical Servs during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in West Pharmaceutical Servs's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to West Pharmaceutical Servs's substantial trades, within a strike price spectrum from $300.0 to $390.0 over the preceding 30 days.
<h3>West Pharmaceutical Servs 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729777546_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$50.7</td>
<td>$47.2</td>
<td>$47.8</td>
<td>$300.00</td>
<td>$463.6K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">694</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$45.5</td>
<td>$44.0</td>
<td>$45.5</td>
<td>$300.00</td>
<td>$455.0K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">498</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$47.8</td>
<td>$47.7</td>
<td>$47.8</td>
<td>$300.00</td>
<td>$305.9K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">694</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$45.5</td>
<td>$44.0</td>
<td>$45.5</td>
<td>$300.00</td>
<td>$291.2K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">398</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$45.4</td>
<td>$43.5</td>
<td>$45.4</td>
<td>$300.00</td>
<td>$290.5K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">182</td>
</tr>
</tbody>
</table>

<h3>About West Pharmaceutical Servs</h3>
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
In light of the recent options history for West Pharmaceutical Servs, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>West Pharmaceutical Servs's Current Market Status</h3>
<ul>
<li>Trading volume stands at 23,145, with WST's price down by 0.0%, positioned at $286.44.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for West Pharmaceutical Servs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On West Pharmaceutical Servs

West Pharmaceutical Services shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 guidance above estimates. Also, the company increased its Q4 dividend.

West Pharmaceutical Services Forecasts Full-Year 2024 Net Sales Guidance Of $2.875B-$2.905B Compared To Prior Guidance Of $2.87B-$2.9B And Consensus Of $2.874B

West Pharmaceutical Services Updates Full-Year 2024 Adjusted EPS Guidance To $6.55-$6.75 Compared To Prior Guidance Of $6.35-$6.65 And Consensus Of $6.51

West Pharmaceutical Services Approves Q4 2024 Dividend Of $0.21/Share, 5% Increase Over $0.20 Per Share Paid In Each Of The Four Preceding Quarters

West Pharmaceutical Servs Q3 2024 Adj. EPS $1.85 Beats $1.50 Estimate, Sales $746.900M Beat $709.616M Estimate

West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) is preparing to release its quarterly earnings on Thursday, 2024-10-24. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect West Pharmaceutical Servs to report an earnings per share (EPS) of $1.50.
Investors in West Pharmaceutical Servs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.22, which was followed by a 2.74% increase in the share price the next day.
Here's a look at West Pharmaceutical Servs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.74</td>
<td>1.26</td>
<td>1.78</td>
<td>1.86</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.52</td>
<td>1.56</td>
<td>1.83</td>
<td>2.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729706518_0.png" alt="eps graph" />
<h3>Performance of West Pharmaceutical Servs Shares</h3>
Shares of West Pharmaceutical Servs were trading at $286.4 as of October 22. Over the last 52-week period, shares are down 12.26%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/WST/earnings">To track all earnings releases for West Pharmaceutical Servs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For West Pharmaceutical Servs

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has fallen 7.45% since its last report. The company recently reported that it has 1.44 million shares sold short, which is 2.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728929714_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.43%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Press Releases

West to Participate in Upcoming Investor Conference

West to Attend and Showcase Industry Leadership in Packaging and Containment at CPHI Worldwide Conference

West Wins Heart of Pharma Award at 2024 CPHI Pharma Awards

West to Host Third-Quarter 2024 Conference Call

West to Present on Large Volume Delivery Systems, Administration and Transfer Devices, and Prefillable Syringe Component Expertise at the PDA Conference

West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend

West to Participate in Upcoming Investor Conferences

West Elects New Director to the Board

West Pharmaceutical Services to Present at the CJS 25th Annual "New Ideas for the New Year" Investor Conference

West Introduces Daikyo PLASCAP® RUV Closures in New Nested Format at Pharmapack


Jared MoskowitzHouse (D-FL)	$1K - $15K	stock	Sale	Dec 09, 2024	Nov 08, 2024	House
Jared MoskowitzHouse (D-FL)	$1K - $15K	stock	Purchase	Jan 22, 2024	Dec 28, 2023	House
Jared MoskowitzHouse (D-FL)	$1K - $15K	stock	Purchase	Aug 21, 2024	Dec 28, 2023	House
Jared MoskowitzHouse (D-FL)	$1K - $15K	stock	Purchase	Aug 21, 2024	Jul 14, 2023	House
Tommy TubervilleSenate (R-AL)	$1K - $15K	stock	Sale	Apr 08, 2022	Mar 30, 2022	Senate

Government Trades

West Pharmaceutical Services Inc

top performing WST trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga